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B
urkitt’s description of an endemic malig-
nancy in Africa raised the question of a
possible infectious etiology for lym-
phoma,1 a question that was strengthened by
the isolation of Epstein-Barr virus (EBV) from
Burkitt’s lymphoma (BL) lymphocytes.2
Although EBV was first associated with BL and
undifferentiated nasopharyngeal carcinoma
(NPC),3 more recent evidence, mainly based on
the detection of EBV-DNA/RNA sequences, has
suggested that this virus may be involved in the
pathogenesis of a wider spectrum of lympho-
proliferative diseases. In the immunocompetent
host these diseases include: Hodgkin’s disease
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ABSTRACT
Considerable evidence has been accumulating in favor of a possible involvement of viral agents in
the pathogenesis of human lymphomas. The most recent proposal for a lymphoma classification,
the Revised European-American Classification, emphasized for the first time the pathogenetic
importance of two viruses, namely Epstein-Barr virus (EBV) and human T lymphotropic virus I
(HTLV-I) in the development of certain lymphoid neoplasias. However, in the last ten years new
viral agents possibly related to lymphoproliferative activity have been discovered: three her-
pesviruses [human herpesvirus-6 (HHV-6), -7 (HHV-7) and -8 (HHV-8)] and a flavivirus, HCV.
HHV-6 was isolated from the peripheral blood of patients with lymphomas and a possible role for
this b-herpesvirus in Hodgkin’s disease and in angioimmunoblastic lymphadenopathy (AILD) has
emerged from serological and molecular studies. HHV-7, a b-herpesvirus genetically close to HHV-
6, has not yet been found in a human disease but it utilizes CD4 as a receptor on the lymphocyte
surface. Only partial HHV-8 genomic sequences have been identified so far, suggesting a genetic
homology with members of the g-herpesvirus family, including EBV. HHV-8 sequences have been
identified for the first time in all forms of Kaposi’s sarcoma as well as in a variety of lymphoid disor-
ders, including body-cavity-based non Hodgkin’s lymphomas, Castleman’s disease, AILD and a
type of HIV-negative reactive lymphadenopathy with peculiar histologic features. Finally, after its
identification as the major cause of post-transfusion and sporadic non-A, non-B hepatitis, HCV has
revealed a lymphotropism both in vitro and in vivo. A strong association between HCV infection
and a benign lymphoproliferative disease, essential mixed cryoglobulinemia type II, has clearly
emerged both from serological and molecular studies. A possible role for this viral infection in B-
cell non Hodgkin’s lymphomas not associated with cryoglobulinemia has also been proposed
recently. The present work offers an overview of the huge amount of experimental and clinical
observations supporting the possible involvement of these new lymphotropic viruses in human
lymphoproliferative diseases.
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(in approximately 50% of cases, predominantly
the mixed cell type),4-6 various T-cell lym-
phomas including angioimmunoblastic lym-
phoma,7,8 angiocentric lymphoma9 and nasal
lymphoma,10,11 and large granular lymphocyte
leukemias from Asian countries;1 2 in the
immunocompromized host: malignant lym-
phomas in boys with the X-linked lymphopro-
liferative syndrome,13 primary cerebral high-
grade B-cell non Hodgkin’s lymphomas
(NHL),14 some systemic lymphomas of the
immunoblastic or large cell type in HIV-1-
infected patients,15 and lymphoproliferative dis-
orders in patients who have undergone organ
transplantation and subsequent immunosup-
pressive therapy.16 Besides EBV, another virus
known to be implicated in human lymphoid
neoplasias is human T-lymphotropic virus type
I (HTLV-I). HTLV-I infection was established
by serological and molecular studies as the
major etiologic factor in adult T-cell leukemia
(ATL) and of a form of cutaneous T-cell
leukemia/lymphoma (CTCL) in endemic
areas.17,18 Very recently, there have also been sug-
gestions that in certain nonendemic areas
HTLV-I may be associated with a number of
CTCLs other than ATL, namely CD30+ anaplas-
tic large cell CTCLs, mycosis fungoides and its
leukemic variant, the Sézary syndrome (SS).19-21
Both EBV and HTLV-I have been studied
extensively and although many aspects of their
biology and interaction with the host are still
obscure, a huge amount of reproducible evi-
dence has been collected in support of a patho-
genetic association between these viruses and
specific subsets of lymphoid neoplasias. The list
of lymphoproliferative diseases demonstrated
to be associated with EBV and HTLV/I is now
perhaps complete and although the mecha-
nisms of viral lymphomagenesis are far from
being understood, the importance of both these
viral agents in the pathogenesis of human lym-
phomas was also emphasized in the Revised
European-American Classification of Lymphoid
Neoplasms, recently proposed by the Interna-
tional Lymphoma Study Group.22
The aim of the present work is to offer an
overview of the latest evidence from the litera-
ture that indicates a possible pathogenetic asso-
ciation between lymphoproliferative diseases in
humans and infection with other, less known,
lymphotropic viruses, most of which have only
been discovered in the last few years (like
human herpesvirus-6 and human herpesvirus-
7) or just one year ago (like human herpesvirus-
8). Furthermore, although we are aware of the
fact that hepatitis C virus cannot be strictly clas-
sified among the classical lymphotropic viruses,
we cannot avoid discussing extensively its possi-
ble association with certain lymphoproliferative
disorders.
HHV-6
HHV-6 was isolated in 1986 from the periph-
eral blood mononuclear cells (PBMC) of six
patients affected with various lymphoprolifera-
tive disorders, some of whom were also infected
with HIV-1.23 HHV-6 is an enveloped virion
containing about 160 kb of linear double-
stranded DNA24 and it is now classified as a b-
herpesvirus.25 This virus has been shown to be
tropic in vitro for cells of the immune system,
namely CD4+ T cells, B cells, NK cells and
monocytes-macrophages; it is also infectious,
although at a lower level, for glial cells and
megakaryocytes.26-28 HHV-6 is ubiquitous in the
human adult population throughout the world,
with seroconversion occurring early in life.29
Primary infection with HHV-6 may cause exan-
them subitum30 and acute febrile illness in young
children,31 while in adults infection may cause
hepatitis32 and a mononucleosis-like syndrome.33
Like all other human herpesviruses, HHV-6 is
probably capable of remaining latent in host
cells subsequent to primary infection and then
may reactivate in an immunocompromized
state, as reported in cases of kidney, liver and
bone marrow transplantation.28 Recently, a con-
sensus was reached on the classification of all
HHV-6 isolates into two groups, called A and
B.25 This distinction is based not only on genetic
and antigenic characteristics but also on the fact
that the isolates from exanthem subitum were
mainly of the B type, while those from immu-
nocompromized patients were mainly of the A
type.28 The virus persists in PBMCs, although
only rare cells are infected in healthy individu-
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als, as demonstrated by studies using poly-
merase chain reaction (PCR).34-36 The idea has
also emerged that the amount of viral copies
harbored in PBMC, is invariably low, not only
in latent conditions but also in conditions of
symptomatic primary infection in children
(exanthem subitum) and of viral reactivation in
post-transplant and HIV immunosuppressed
patients, in whom HHV-6 sequences can never
be detected by Southern blot analysis but only
by the sensitive PCR technique. The level of
viral genomes in PBMC does not correlate with
anti-HHV-6 antibody titers, and these cells are
certainly not the only site of viral latency/persis-
tence. In fact, the oropharynx and/or salivary
glands,37 the epithelial mucosa of the female
genital tract28 and brain tissue38-40 may harbor
viral genomes and represent a reservoir of the
virus in the healthy population. The state of the
viral genome in infected host cells has not been
fully investigated. The entire HHV-6 genome
was found to be integrated in the short arm of
chromosome 17 (17p13.3) in the PBMCs of
three patients (one each with NHL, HD, and
multiple sclerosis) harboring extraordinarily
high levels of the viral genome.41,42 In particular,
the order of the HHV-6 viral integration site rel-
ative to two known genes, ABR and CRK,43 was
recently mapped in the PBMCs of the NHL
patient, and the results place the HHV-6 inte-
gration site very close to, if not within, the telo-
meric sequences on 17p (manuscript in prepa-
ration). However, given the abnormally abun-
dant HHV-6 DNA and the altered immune sta-
tus of the hosts, it is still unclear whether this
phenomenon of targeted chromosomal integra-
tion is also common to other clinical conditions
and/or to the healthy population, possibly rep-
resenting a usual mechanism of HHV-6 latency
in vivo. 
A possible pathogenetic role for HHV-6 in
lymphoproliferative diseases was first suggested
by the ability of its DNA, either as a complete
genome or as specific cloned fragments, to trans-
form established NIH 3T3 cells and human epi-
dermal keratinocytes in vitro, causing them to
form rapidly growing and metastasizing tumors
when injected into nude mice.44-46 In addition, a
gene homologous to the so-called rep gene of
human adeno-associated virus type 2 (AAV-2)
has recently been identified in the HHV-6
genome.47 The HHV-6 expression of a gene act-
ing as a modulator of heterologous gene expres-
sion and cellular transformation is likely to have
important consequences for infected host cells.48
Thus, HHV-6 was considered an  oncogenic
virus candidate from the very beginning because
of its presence in cases of human lymphomas
and its in vitro transforming potential.
Seroepidemiology has proven to be an impor-
tant tool for linking viruses with cancer and
other disorders. A role for HHV-6 infection in
HD was first suggested by serological studies
showing that anti-HHV-6 antibody titers were
higher in HD than in normal blood donors49,50
(Table 1) and that they were related to the evolu-
tion of the disease, rising during HD relapse and
falling in non relapsing patients.51 By contrast,
the levels of anti-HHV-6 antibodies in NHL
patients have been found to be similar to those
documented in the healthy population50,52 (Table
1). On the other hand, serological features alone
are a suggestive, but certainly not a conclusive
argument for the causal role of a virus in human
pathology, and identification of the viral genome
in pathologic specimens is considered crucial for
determining the viral etiology of a disease. This
caveat is likely to hold especially true for HHV-6,
Table 1. HHV-6 infection in lymphoproliferative diseases and in the normal
population.
References Anti-HHV-6 HHV-6 sequences
antibodies by IFA by PCR and 
at 1:40 dilution Southern blot
(% positive cases) 
HD Torelli et al. (50) 80 12
Di Luca et al. (53) n.d. 29
NHL Josephs et al. (57) n.d. 6
Jarrett et al. (58) n.d. 2
Torelli et al. (50) 62 0
Di Luca et al. (53) n.d. 0
AILD Luppi et al. (59) n.d. 58
Blood donors Di Luca et al. (53) n.d. 17
Torelli et al. (50) 54 n.d.
Luppi et al. (36) 54 20
HD: Hodgkin's disease; NHL: non Hodgkin's lymphoma; AILD: angioimmunoblastic
lymphadenopathy; IFA: indirect immunofluorescence assay; n.d.: not done.
 
since unusual cases of herpesvirus latency have
been described in which the absence of anti-
HHV-6 IgM and IgG antibodies was matched by
an unexpectedly high number of viral sequences
in the PBMC of patients with lymphoprolifera-
tive disorders.41 This is the reason for combining
molecular methods with serologic studies to
search for HHV-6 genomes, in order to avoid the
risk of missing patients with a latent infection
but negative serology. With the aid of PCR,
HHV-6 specific sequences have been detected in
the pathologic tissues of about 30% of the HD
patients examined so far, and variant B has been
more frequent than variant A53 (Table 1). The
majority of HD biopsies positive for HHV-6
belonged to the nodular sclerosis type, although
a significant fraction of mixed cellularity and
lymphocyte prevalence types also harbored
HHV-6 sequences. Thus the frequency of HHV-
6 sequences in HD tissues is slightly higher than
in the PBMCs of the healthy population, evalu-
ated to be about 17% under the same PCR con-
ditions, supporting the idea that this virus might
be associated with a subset of this disorder53
(Table 1). Of interest, the only three cases found
to be positive for HHV-6 DNA in a well-charac-
terized series of twenty-five HD cases presented
remarkable similarities.50 In particular, the three
patients, all young women, showed mesothelial
effusions (pleuropericardial in two cases and
pleuroperitoneal in the third). Two of them fea-
tured a predominant bulky mediastinal involve-
ment, while the third patient showed mediasti-
nal involvement as part of a generalized disease.
All three cases belonged to the same histologic
subgroup, nodular sclerosis-lymphocyte deple-
tion, which generally accounts for a small pro-
portion of HD cases and is associated with poor
prognosis.50 Although a relationship between the
presence of HHV-6 and a particular subset of
patients has not been solidly established, the
possibility has been raised that HHV-6 infection
may play a role in determining some basic clini-
cal aspects of a limited number of cases. In two
of these patients the level of viral sequences was
extraordinarily high, so as to be easily detected
not only by PCR but also, unexpectedly, by
Southern blot analysis, which also revealed the
presence of the B variant of HHV-6 with the
same restriction fragment length polymor-
phisms in both cases. Of interest, Southern blot
analysis also detected the presence of the entire
viral genome in the pathologic lymph nodes and
PBMCs of one patient, while documenting the
deletion of the viral region containing the rep
gene localized at the 3’ end of the HHV-6
genome in the lymphomatous tissue of the other
HD patient.42,54 Although rep gene products have
been shown to regulate the promoter/enhancer
elements of a variety of cellular genes and to
exert anti-proliferative activity in vitro, it is not
possible at present to determine the biological
consequences, if any, of either the presence or
the absence of this gene in the HHV-6 infected
cells of the HD patients examined. Of interest,
while the patient infected with the complete
HHV-6 genome achieved a complete remission
that has lasted for 7 years, the other HD patient
with a defective virus had an unfavorable clinical
course and died 11 months after diagnosis,
despite an initial response. The possibility that
the presence of the rep gene may be related to a
favorable clinical disease course  is intriguing,
but is still only a matter of speculation because
of the small number of cases studied.54 In any
event, HHV-6 genomes that show variations in
the genomic structure with respect to the A and
B prototypes, although infrequent, do exist and
must be kept in mind. In fact, another HD case
of the mixed cellularity type, found positive for
HHV-6 by Southern blot, showed abnormal
cleavage patterns after digestion with various
restriction enzymes, indicating gross alterations
and/or rearrangement within the viral region
homologous to the probes used.55 The relevance
of these abnormal HHV-6 variants in terms of
pathogenicity deserves further investigation.
Finally, we have  examined HD lymph nodes by
immunohistochemistry in our laboratory (in
collaboration with R. Garber, PathoGenesis
Corporation, Seattle, USA) using the monoclon-
al antibody p41/38, which recognizes a DNA
replication factor, a protein whose function is
still unknown but that is likely to be expressed in
the early phase of the HHV-6 replicative cycle.
This viral protein has clearly been shown to be
expressed only in a significant number of Reed-
Sternberg cells and in plasma cells, but not in the
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reactive cellular population of HD lymph node
tissues, representing the first unequivocal
demonstration of HHV-6 in the putative neo-
plastic element of HD (manuscript in prepara-
tion). However, the assessment of HHV-6
involvement in HD will require defining the
exact functions of this viral protein found in
Reed-Sternberg cells, as well as identifying which
HHV-6 proteins, if any, have transforming prop-
erties, analogously to the detection of the onco-
genic latent membrane protein of EBV in the
Reed-Sternberg cells of most cases of mixed cel-
lularity type HD.
HHV-6 sequences have rarely been detected in
pathologic tissues from NHL cases of B and T
cell lineage50,52,53 (Table 1). With sensitive PCR,
the frequency of HHV-6 sequences in malignant
lymphoma tissues was similar to that found in
the PBMCs of the general population and
increased only in patients with AIDS, probably
due to reactivation of HHV-6 infection as a
result of immunosuppression.56 Only six out of
the hundreds of NHL cases examined so far
throughout the world (one of T and five of B
cell lineage) have been found to harbor such a
high viral load as to be detectable by Southern
blot.41,57,58 The entire viral genome was found to
be integrated in the pathologic lymph node of
one of these B cell NHL, but in situ hybridiza-
tion studies were not performed to identify the
cellular elements, either neoplastic or reactive,
harboring the HHV-6 DNA.42 On the other
hand, integration of the HHV-6 genome was
also demonstrated in PBMCs from the lym-
phoma patient in complete remission, i.e. in
cells probably not involved in the neoplastic
process, suggesting that in HHV-6 infection the
integration process  per se is not a direct cause of
lymphoid neoplasia.42 However, based on the
direct oncogenic potential as well as on the
putative, positive and/or negative regulatory
functions of some viral genes, the presence of an
integrated HHV-6 genome in the neoplastic
lesion may suggest a pathogenetic role for this
lymphotropic virus, at least as a modulating ele-
ment, in the lymphoproliferative process of this
patient. Among NHL, angioimmunoblastic
lymphoma represents an exception. In fact,
using PCR, HHV-6 DNA sequences were detect-
ed in three out of four angioimmunoblastic
lymphadenopathy-like (AILD-like) lymphoma
and in four out of eight angioimmunoblastic
lymphadenopathy biopsies, with an approxi-
mately equal distribution between the A and B
variants and one case of coinfection59 (Table 1).
Three of the seven HHV-6-positive specimens
were simultaneously positive for EBV sequences,
suggesting the possibility of an interaction
between these two viruses in these tissues, espe-
cially given the ability of HHV-6 to activate EBV
replication in vitro.60 Although the cause of
AILD is unknown and is likely to vary in differ-
ent subjects, one common feature is excessive
immunity, which leads to characteristic lymph
node histology and clonal expansion of B and T
lymphocytes. Therefore HHV-6 may be
involved in the pathogenetic mechanisms of
AILD by acting as a trigger, mainly through
swithing on T cell activity, at least in the initial
phase of the disease, which is characterized by
the presence of activated T cells in the lymph
nodes as well as in the peripheral blood, where
most T cells express HLA-DR antigens. On the
other hand, it is not possible to rule out the
hypothesis that the presence of HHV-6, as well
as of other viruses like EBV and HHV-8 (see
below) may be a reflection rather than a cause of
a disease process that is strictly related to the
abnormal immunoregulation typical of this
condition. In this view, HHV-6 itself may con-
tribute to the immune impairment, given its
proven ability to interfere with the cells of the
immune system, mainly T cells, as well as with
various cytokine networks.61,62 At present, the
mechanisms of HHV-6 infection involvement in
the pathogenesis of AILD are obviously only a
matter of speculation; however, the frequent
detection of the HHV-6 genome in AILD and
AILD-like lymphoma cases remains a very pecu-
liar and distinctive phenomenon not found in
other lymphoproliferative diseases, even though
they are also associated with a marked impair-
ment of the immune response.
Other instances of HHV-6 being found in
lymphoid disorders include one case of S100
chronic lymphoproliferative disease showing
variant B HHV-6 genome and HHV-6 RNA in
tumor cells,63 and one case of large granular
269Lymphotropic virus in human lymphoproliferative diseases
lymphocytic leukemia transformation during
the course of a reactivated HHV-6 infection.64
An association has also been proposed between
HHV-6 infection and sinus histiocytosis with
massive lymphadenopathy (Rosai-Dorfman dis-
ease), a condition characterized by an accumu-
lation of histiocytes in lymph node sinuses that
leads to a painless cervical lymphadenopathy.
HHV-6 sequences were found by in situ
hybridization in pathologic tissues from seven
out of nine cases of Rosai-Dorfman disease.65
These findings suggest HHV-6 tropism for histi-
ocytes in vivo, a fact confirmed by the detection
of HHV-6 DNA in histiocytes but not in T cells
in all the forms of lymphadenitis studied so far.28
The role of HHV-6 in acute lymphoblastic
leukemia (ALL) is controversial, with only one
study on a small group of ALL patients docu-
menting higher levels of anti-HHV-6 antibodies
than in normal subjects;66 another study on a
larger number of ALL patients and normal
blood donors did not observe any significant
differences in the anti-HHV-6 antibody titers of
the two groups.67 Moreover, HHV-6 sequences
were first detected by PCR and in situ hybridiza-
tion in the bone marrow cells of the majority of
children with T-ALL,68 but a subsequent study
showed that the presence of HHV-6 DNA is no
more frequent in patients with ALL than in nor-
mal subjects.69 Moreover, in ALL cases as in
healthy individuals, HHV-6 infection is invari-
ably characterized by a very low copy number of
viral sequences detectable only by highly sensi-
tive PCR, arguing against a major role for HHV-
6 in this disease. 
It is difficult to put all these observations into
a coherent sequence of events to explain the
clinical relationship between HHV-6 and lym-
phomagenesis. It is also difficult to differentiate
between a virus that is a passenger in tumor tis-
sue and one that plays a role in the etiology of
the neoplasm, and the observations reported
above regarding the presence of the HHV-6
genome in various lymphoma tissues should
not be taken as proof of etiology. It should be
kept in mind for HHV-6 as well as for other
viruses like EBV and HTLV-I in endemic areas
that the prevalence of viral infection is always
much higher than the incidence of the associat-
ed disease. HHV-6 is a ubiquitous infectious
agent with a long evolutionary relationship with
its human host. Primary infections in adults are
rare and although they appear to have more
severe consequences than normal childhood
acquisition, they are commonly associated with
non neoplastic diseases, i.e. prolonged benign
lymphadenopathy or mononucleosis-like illness.
Thus, it is unlikely that HHV-6 has a major
oncogenic effect, and it is conceivable that this
herpesvirus may contribute to lymphomagene-
sis only under particular conditions of host
immunosuppression or when specific viral pro-
teins are expressed in an unusual cell type, as in
the case of Reed-Sternberg cells in some HD
cases. The effect of an oncogenic virus is gener-
ally to initiate a multistage process of lym-
phomagenesis by expressing proteins able to
interact with host cell-encoded tumor-suppres-
sor proteins and to abrogate the cell cycle check-
point functions, thereby predisposing the cell to
genetic instability. In the case of EBV for exam-
ple, the lytic cycle protein BZLF1, rather than a
latent protein, has been shown to abrogate p53
function.70 However, specific HHV-6 oncopro-
teins able to bind to and functionally inactivate
tumor suppressor proteins have not yet been
identified, and the mechanisms through which
this herpesvirus might affect the growth control
of infected cells are far from being elucidated.
Furthermore, in order to participate in cancer
development DNA tumor viruses have to
remain in infected cells for long periods without
reproducing infectious viral particles.71 It is still
unclear whether HHV-6, which is cytopathic in
vitro, has the ability to establish long-term laten-
cy in the host in vivo, a condition necessary for
the accumulation of the additional genetic
changes that mediate malignant progression in a
virally infected cell. Targeted integration of the
HHV-6 genome into the chromosomal DNA of
the host cell may represent one important
mechanism by which HHV-6 is capable of
remaining in the latent state, but this type of
latency seems rather infrequent since it has only
been described in the PBMCs of a few patients
with lymphoproliferative and immune disor-
ders. Thus more information on HHV-6 laten-
cy/persistence and on viral interaction with
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infected cells in vivo is needed to ascertain the
role of this herpesvirus in the etiopathogenesis
of human lymphoid neoplasias. 
HHV-7
HHV-7, like HHV-6, is a member of the b
subgroup of herpesviruses. The first two viral
isolates of HHV-7 were obtained from the
peripheral blood of a healthy individual72 and of
a patient with the so-called chronic fatigue syn-
drome.73 Subsequently, HHV-7 was isolated
from saliva in a high proportion of healthy
adults,74 suggesting that it can replicate in vivo,
at least in selected sites, without clinically appre-
ciable consequences. HHV-7 has a selective tro-
pism for CD4+ T lymphocytes, and the glyco-
protein CD4 is an essential component of the
cellular membrane receptor for HHV-7.75 In
fact, marked reciprocal interference between
HHV-7 and HIV, which also uses CD4 as a
receptor, has been observed in in vitro experi-
ments.75 Furthermore, it appears that HHV-7
reactivates latent HHV-6 genomes, an in vitro
observation which might have clinical relevance.
At this time, HHV-7 has not been linked to any
human disease. Of interest, HHV-7 has been
isolated from the PBMCs of a Japanese child
suffering from recurrent fever, hepato-
splenomegaly and pancytopenia, an illness clini-
cally indistinguishable from chronic active EBV
infection.76 This finding raises the possibility
that HHV-7 might play a role in lymphoid dis-
orders, although further studies are needed to
confirm the pathogenic potential of this her-
pesvirus in vivo.
HHV-8
Evidence for the most recent putative human
herpesvirus was obtained using molecular tech-
niques. Novel specific DNA sequences were first
identified in Kaposi’s sarcoma (KS) tissues from
patients with AIDS, using the representational
difference analysis (RDA) technique.77 The
reported sequences of the apparently KS-specific
DNA segments showed partial similarity to two
capsid protein-coding genes of known g-her-
pesviruses, namely EBV and herpesvirus saimiri
(HVS).77 The presence of these sequences argued
in favor of the existence of a new human her-
pesvirus called KS virus (KSHV)77 or, more
recently, HHV-8.7 8 These herpesvirus-like
sequences could be amplified by PCR in the vast
majority of KS biopsies, not only the AIDS-
associated79 but also the endemic80-82 and classic
types,83,84 suggesting that this putative new
human herpesvirus might not be solely an
opportunistic infectious agent but possibly an
essential agent involved in all the different forms
of KS. KS-associated herpesvirus sequences have
been found in all the different stages of KS84,85
and have been unequivocally identified by PCR
in situ hybridization both in the endothelial and
in the typical KS spindle cells, thought to repre-
sent the neoplastic elements in these lesions.86
The presence of HHV-8 is not, however,
exclusive to KS lesions and evidence has been
accumulating to indicate that these putative new
herpesvirus sequences are associated with spe-
cific lymphoid disorders (Table 2). In fact,
HHV-8 sequences have been documented in the
vast majority of AIDS-related, body cavity-
based B cell NHL cases examined so far in the
USA87 and in Europe.88 These lymphomas are
characterized by pleural, pericardial or peri-
toneal lymphomatous effusions in the absence
of a contiguous tumor mass and probably repre-
sent a distinct category of AIDS-related lym-
phomas because of their unusual clinical, mor-
phological and immunophenotypic features.
Rearrangement of the immunoglobulin genes,
the presence of a clonal EBV genome, the
absence of myc rearrangement and immuno-
phenotypic characteristics associated with the
late stages of B cell differentiation are constant
features of these lymphomas.87 Few cases of
body cavity-based B cell lymphomas occurring
in HIV-negative subjects have been also
described with the same characteristics.89,90 Two
cell lines derived from AIDS-related, body cavi-
ty-based B cell lymphomas have been estab-
lished that show viral sequences in episomal
structures.91 The HHV-8 association seems to be
almost exclusive for this unusual type of lym-
phoma, since hundreds of HIV-positive and
negative cases of HD and B- and T cell NHL
examined so far have invariably been nega-
 
tive.87,88,92 This finding apparently suggests a
selective lymphomagenetic role for HHV-8 in
vivo. 
HHV-8 sequences have also been identified in
pathologic lymph node tissues from a signifi-
cant number of cases of HIV-positive and nega-
tive multicentric Castleman’s disease (MCD),93-95
which is an atypical lymphoproliferation with a
known increased risk of developing KS,96 but the
pathogenetic role, if any, of the virus in this par-
ticular disease is merely speculative.93 MCD
lymph nodes may be asymptomatically infected
by HHV-8, which would then be only a passen-
ger in this lesion.93 Alternatively, the cellular
proliferation seen in MCD may be related to this
herpesvirus acting as a cofactor, perhaps as a
stimulus for cytokines, in a context of immune
dysregulation.93
Furthermore, three patients with another
atypical lymphoproliferation, namely AILD,
were shown to harbor HHV-8 sequences in
pathologic tissues, but again a pathogenetic link
with the virus can only be hypothesized.92
Excessive immunity is a typical feature of AILD,
and much speculation has centered around the
possibility that a viral infection could directly or
indirectly trigger this disorder. In particular,
human herpesviruses like EBV and HHV-6 have
already been found to be associated with AILD,
so it is not totally unexpected that this new
putative herpesvirus, which belongs to the fami-
ly of lymphotropic g-herpesviruses, should be
found in at least some cases of AILD.92 On the
other hand, the disease etiologically related to
the presence of HHV-8 sequences, i.e. KS, is
itself characterized by chronic immune activa-
tion and release of inflammatory cytokines, so
that common immune dysfunctions underlying
both disorders could be hypothesized.9 2
Furthermore, at least 9 well-documented cases
of KS have been reported in patients with
AILD,97 and vascular hyperplasia is characteristi-
cally observed in both pathologic lesions.
Of interest, HHV-8 sequences were identified
in 4 out of 5 cases of HIV-negative reactive lym-
phadenopathies, all showing the same histologic
features characterized by florid germinal center
hyperplasia associated with varying degrees of
condensation and regression of germinal centers
in the presence of increased vascularity and
monocytoid B cell hyperplasia.92 Examination of
the clinical records of the 4 HIV-negative
patients with HHV-8-positive lymphadeno-
pathies revealed that in all cases lymph node
enlargement was localized and not accompanied
by hepatosplenomegaly. Fever and constitution-
al symptoms were absent, and no laboratory
abnormalities indicative of viral or other infec-
tions were documented. Marked thrombocy-
topenia was also present in two of them at the
time of lymph node enlargement.92 The histo-
logic features of the florid germinal center
hyperplasia recognized in the 4 HHV-8-positive,
HIV-negative benign lymphadenopathies can be
observed in a number of other clinical condi-
tions like autoimmune disorders (especially
rheumatoid arthritis and Sjögren’s syndrome),
MCD and HIV infection.98 In fact, some cases of
persistent generalized lymphadenopathy have
also been found to harbor these viral
sequences.77 In addition, vascular hyperplasia is
a common feature of all the HHV-8-positive
lesions identified so far, including KS, MCD,
AILD and the above described lymphadeno-
pathies. In other words, the histologic features
recognized in these HHV-8-positive cases of
reactive lymphadenopathies represent a defined
pattern of  lymph node response, possibly
induced by a wide range of antigenic stimuli,
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Table 2. HHV-8 sequences in lymphoproliferative disorders.
Diagnosis No. of cases No. of positive cases Ref.
Non-AIDS
HD and NHL 382 2 (87,88,89, 92,94,104)
MCD 28 8 (93,94)
AILD 15 3 (92)
Reactive lymphadenopathies
55 5 (92,93)
AIDS
HD and NHL 99 15 (87,88, 92,94,95)
MCD 20 19 (93,94,95)
PGL 31 8 (77,92,93,94)
HD: Hodgkin's disease; NHL: non Hodgkin's lymphoma; MCD: multicentric
Castleman's disease; AILD: angioimmunoblastic lymphadenopathy; PGL: persistent
generalized lymphadenopathy.
and HHV-8 should now be considered in the
differential diagnosis of the possible causes for
this response. This peculiar histologic pattern of
lymphoid response induced by HHV-8 is likely
to reflect the original pathogenic potential of
this herpesvirus in HIV-negative subjects.92
Therefore these lymphadenopathy cases may
represent the possible clinicopathologic condi-
tion, benign in nature, which might develop
during primary HHV-8 infection in normal
subjects, just as infectious mononucleosis repre-
sents the most common clinical manifestation
of EBV infection in the general population. The
possibility still remains that HHV-8 may exhibit
indirect transforming ability in conjunction
with other factors, like EBV, as has been pro-
posed for the subgroup of body cavity-based
lymphomas.87 However, three of the four HHV-
8-positive lymphadenopathies also harbored
EBV sequences, suggesting that the presence of
EBV together with HHV-8 is not necessarily
associated with the full neoplastic phenotype.92
Like other herpesviruses, HHV-8 could be a
benign agent responsible for the reactive lym-
phadenopathies described above, or it could be
associated with malignant conditions like KS or
body cavity-based lymphomas. At present, it is
not known whether HHV-8 is an oncogenic
virus or if it simply infects a subset of B lym-
phocytes which tend to proliferate in response
to a developing cancer.78 Alternatively, analo-
gously to EBV, this virus might play a role in
promoting malignancy by enhancing the prolif-
eration of infected B cells and thus the rate of
spontaneous or induced mutational events.78
Finally, there is even the possibility that HHV-8-
infected B cells are capable of producing
cytokines that may in turn stimulate the growth
of other B cell populations, leading to a malig-
nant proliferation.78,99 Isolation of this her-
pesvirus and study of its possible oncogenic
properties in vitro, together with an analysis of
the cytokine profiles released by HHV-8-infect-
ed cells, will give insights into the effective role
of HHV-8 in human lymphomagenesis.78
HHV-8 is a widespread virus but, like EBV, it
is probably undetectable in many individuals.78
HHV-8 might be harbored in latently infected
cells/tissues, such as circulating B cells,100 ton-
sils84 or semen,101 and be sometimes reactivated
by AIDS-related and/or therapeutic immuno-
suppression. In fact, these viral sequences have
been found in various proliferative non KS skin
lesions in immunocompromized organ trans-
plant patients,102 as well as in the PBMCs of a
patient who developed KS after allogenic bone
marrow transplantation.103 A case of HHV-8-
associated primary cerebral B cell lymphoma
was recently described in an HIV-negative
patient treated for years with prednisone
because of an idiopathic uveitis.104 It is conceiv-
able that this particular clinical situation, char-
acterized by prolonged steroid therapy, com-
bined with subtle immunological defects associ-
ated with the uveitis might have contributed to
the reactivation of HHV-8 in this patient with
cerebral lymphoma. It should also be noted that
a few cases of EBV-associated B cell lymphomas
have already been reported in patients treated
with cyclosporine and methotrexate for
rheumatoid arthritis and dermatomyositis.105,106
Analogously to EBV and its proposed role in
promoting human lymphomagenesis, it is also
possible to speculate on the involvement of
HHV-8 in the multistep development of some B
cell lymphomas that occur in certain immuno-
suppressed patients.
HCV
The cloning of HCV was achieved in 1989 in
the absence of an observed viral particle from
cDNA of infectious chimpanzee plasma,107 and
within one year the entire viral genome was
sequenced and many of its structural and func-
tional properties were defined.108,109 HCV is a
small single-stranded, positive-sense RNA virus
of about 9,500 bases coding for about 3,000
amino acids, and is now considered a new
member of the Flaviviridae.110 HCV has no DNA
intermediate and therefore cannot integrate into
the host genome, but it does use negative-strand
RNA in its replicative cycle in the liver.1 1 0
Sequence analysis of specific regions of the viral
genome has allowed classification of HCV vari-
ants into six major groups.111 Distinction of
HCV genotypes is important since the outcome
of HCV disease and the response to antiviral
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therapy with interferon correlates with the HCV
type. In fact, genotype 1 (in particular  subtype
1b) has been associated with more severe chron-
ic liver disease and poor response to interferon
therapy.112-114 HCV has a high spontaneous
mutation rate and as a result it exists as a het-
erogeneous group of viruses that show about
70% homology overall, similar to that of other
flaviviruses.109 This coexistence of multiple
mutants has been termed quasi-species and it
provides a very efficient and rapid mechanism
for the virus to elude the immune response and
persist in the host. HCV infection persists in
about 80% of cases.115 During persistent HCV
infection anti-HCV antibodies with different
specificities can be detected, but these antibod-
ies do not lead to clearance of, or immunity to,
the virus. The main route of transmission is
parenteral.116 Recent data showed an unexpect-
edly frequent patient-to-patient transmission of
HCV in a hematology ward despite strict
hygienic control, raising concern about spread
through previously unsuspected contaminated
sources.117 HCV has been identified as the
causative agent of different chronic liver dis-
eases, including post-transfusion and sporadic
non-A, non-B hepatitis,118 as well as autoim-
mune chronic hepatitis.119,120 Chronic infection
with HCV is considered a risk factor for hepato-
cellular cancer, mostly in patients with liver cir-
rhosis, although very recently it has been sug-
gested that HCV infection, mostly genotype 1b,
is directly associated with the development of
hepatocellular cancer without the intermediate
step of cirrhosis.121
It should be noted that HCV is not only hepa-
totropic but it is also a lymphotropic virus able
to replicate in vitro in a human T cell line.122
Furthermore, viral genomic sequences have
been found in both peripheral T and B cell pop-
ulations as well as in the monocyte-macrophage
fraction of HCV-related chronic hepatitis.123
Recently, HCV infection has been documented
in the vast majority of patients with essential
mixed cryoglobulinemia (MC) type two124,125
(Table 3). This is a benign lymphoproliferative
disorder characterized by the presence of tem-
perature sensitive protein complexes formed by
polyclonal IgG and monoclonal IgM rheuma-
toid factors. Clonal expansion of IgMk-bearing
B cells in peripheral blood, lymphoid aggregates
in bone marrow biopsies and lymphocytic infil-
tration of liver, spleen or kidneys have been
reported in MC patients, confirming the lym-
phoproliferative nature of the disease, which,
however, evolves into a frank B cell NHL only in
a minority of cases and generally after a long
follow-up.126 Anti-HCV antibodies were first
documented in 42% of 19 patients with type II
cryoglobulinemia and HCV RNA was detected
in 84%, while controls with type I cryoglobu-
linemia proved to be negative for these mark-
ers.127 Furthermore, anti-HCV antibodies and
HCV RNA were found to be concentrated 10-
and 1,000 fold, respectively, in the isolated cryo-
precipitate.127 The striking association of HCV
infection with MC was also supported by a sub-
sequent study documenting the presence of
anti-HCV antibodies in 100% of 16 patients
with type II (IgMk) MC studied by ELISA and
confirmed by RIBA.128 Moreover, HCV RNA was
Table 3. HCV infection in lymphoproliferative diseases.
Anti-HCV antibodies HCV RNA sequences 
References (% positive cases) (% positive cases)
by ELISA and RIBA by RT-PCR
EMC Agnello et al. (127) 42 84
Ferri et al. (128) 100 81
Pozzato et al. (129) 84 96
Luppi et al. (139) 84 n.d.
B-NHL in EMC
Ferri et al. (130) 100 100
B-NHL Ferri et al. (137) 30 32
Luppi et al. (139) 42 30
Cavanna et al. (138) 25 n.d.
B-CLL Cavanna et al. (138) 5 n.d.
Luppi et al. (139) n.d. 0
PCD Luppi et al. (139) 12 n.d.
Cavanna et al. (138) 16 n.d.
HD Ferri et al. (137) 4 0
Cavanna et al. (138) 10 n.d.
Luppi et al. (139) 1 8
EMC: essential mixed cryoglobulinemia; B-NHL: B cell non Hodgkin's lymphoma; B-
CLL: B-cell chronic lymphocytic leukemia; PCD: plasma cell dyscrasia; HD: Hodgkin's
disease; n.d.: not done.
documented in the sera of 50% of the same
patients by RT-PCR, and its frequency markedly
increased to 81% when genomic sequences were
detected in peripheral lymphocytes, suggesting
that these cells could represent the viral reser-
voir of HCV infection.128 On the other hand, the
fact that HCV infection has been found in sev-
eral MC cases in the absence of any clinical, bio-
chemical or pathological evidence of liver dam-
age indicates that in these cases MC cannot be
considered as a mere extrahepatic manifestation
of HCV-related chronic hepatitis. HCV geno-
typing has also demonstrated the occurrence of
multiple genotypes and coinfections with differ-
ent variants in MC patients.129 Of interest, both
serological and molecular markers of HCV
infection have also been documented in 100%
of 10 patients with B cell NHL complicating
MC130 (Table 3). Although various independent
studies have now unequivocally confirmed the
close relationship between HCV infection and
MC, and although it appears that immune com-
plexes involving HCV are intimately involved in
cryoprecipitate formation, the pathogenetic
pathways of this interaction are still unknown.
Nonetheless, it has been proposed that the anti-
genic stimulus represented by HCV may induce
complex cellular and humoral autoreactivity
through different mechanisms, such as molecu-
lar mimicry or altered auto-antigens. As a con-
sequence, the persistence of HCV in the
immune system could greatly expand clones of
Ig (cryoglobulin)-secreting lymphocytes by a
direct or indirect mechanism, and a mutational
event could eventually lead to activation of
oncogenes, resulting in a B cell neoplasia.124 One
patient with MC and HCV infection was
reported to develop a monoclonal multistep
lymphoproliferative disorder that was first asso-
ciated with bcl-2 translocation in the benign
phase of the disease, and then with a second
genetic alteration, the translocation of the myc
oncogene, in the accelerated phase of the clinical
course of the disease.131
It should also be considered that a-interferon
(IFN) currently seems to be the drug of choice-
for treating MC, since it reduces symptoms and
cryoglobulin production.126 IFN shows antipro-
liferative action as well as antiviral effects, which
are useful in HCV-related MC.132,133 Long-term
IFN therapy might be useful for controlling
HCV replication and thus for preventing low-
grade NHL, which is documented in the bone
marrow in a significant percentage of MC
cases.129 Recently, the number of nucleotide
mutations in the nonstructural protein NS5A
was reported to correlate with the response to
IFN in patients with chronic HCV 1b infec-
tion.134 The possible clinical relevance of this
phenomenon in the treatment of HCV-related
MC has not yet been ascertained.
It was also recently reported that in a popula-
tion of 500 patients with HCV hepatitis, 14
developed diffuse B cell NHL (8 low, 5 interme-
diate and 1 high-grade), supporting the notion
that B cell NHL can be a harmful complication
of chronic hepatitis type C able to change the
prognosis of the disease.135 The finding of sero-
logic and molecular markers of HCV infection
in a small series of patients with Waldenström’s
macroglobulinemia (WM), a rare B lymphocyt-
ic neoplasia characterized by monoclonal pro-
duction of IgM, also argues in favor of a possible
role for this viral infection not only in benign
but also in neoplastic IgM gammopathies.136
Antibodies against HCV and HCV genomic
sequences have been documented in the sera of
over one third of a series of unselected Italian B
cell NHL cases not associated with MC, thus
suggesting the involvement of this virus in a
wider spectrum of B cell clonal lymphoprolifer-
ations.137 This unexpectedly high prevalence of
anti-HCV antibodies in Italian patients with B
cell NHL not associated with MC (ranging from
25% to 42% in different studies) was indepen-
dently confirmed138,139 (Table 3), and is particu-
larly significant when compared with the preva-
lence of HCV seropositivity in the healthy
Italian population (1-3%).138,140 Moreover, the
prevalence of anti-HCV antibodies is invariably
low in the group of patients affected with mon-
oclonal gammopathies without cryoglobuline-
mic activity, namely multiple myeloma (MM),
WM and monoclonal gammopathy of undeter-
mined significance (MGUS),139 as well as in the
group of patients with chronic lymphocytic
leukemia (CLL)138 (Table 3). This suggests that
the activation of an immune response against
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HCV infection is not a general phenomenon in
all B cell lymphoproliferative disorders, but is
likely to be restricted to certain histologic sub-
types. Furthermore, HCV-specific genomic
sequences have been identified by RT-PCR
directly in pathologic lymph node tissues from
13 out of 34 B cell NHL cases, and in particular
in 6 out of 8 low-grade MALT type lymphomas
and in five out of eight centroblastic-centrocytic
follicular lymphomas.139 This finding is unex-
pected and in contrast with the absence of viral
RNA in T cell NHL samples and the majority of
HD cases analyzed by RT-PCR in the same
study. More importantly, neither peripheral
blood samples nor pathologic lymph nodes
from 14 patients with B-CLL/small lymphocytic
lymphoma harbored HCV sequences.139 Such
marked differences in the prevalence of HCV
RNA in neoplastic tissues between some B cell
NHL (MALT and centroblastic-centrocytic fol-
licular types) and other B neoplastic prolifera-
tions like CLL, or T cell NHL or HD clearly sug-
gest that events like exposure to blood products
or prolonged hospitalization are unlikely to
account for the higher prevalence of this viral
infection in certain types of B-NHL. Similarly,
the immune impairment common to all these
patients and in particular to CLL patients does
not seem to be responsible for the observed dif-
ferences in the distribution of HCV sequences
among various subsets of neoplastic lympho-
proliferations.139 An association between HCV
infection and low-grade MALT type lymphoma
has also been suggested by the detection of anti-
HCV antibodies by ELISA and RIBA, as well as
of HCV sequences by RT-PCR in the sera of 8
out of 16 patients with MALT lymphoma
(Luppi et al. submitted). Several chronic inflam-
matory conditions, most of which have shown
an autoimmune component, including
Helicobacter pylori (HP)-induced chronic gastri-
tis, Sjögren’s syndrome and Hashimoto’s thy-
roiditis, result in the acquisition of MALT-like
lymphoid tissue and have been identified as pre-
cursors in the development of MALT lym-
phoma. The possibility now arises that HCV is a
potential infectious cofactor, along with HP, in
the multistep transformation of low-grade
MALT type lymphoma.
In conclusion, the detection of both serologic
and molecular markers of HCV infection in a
relevant percentage of B cell NHL not associated
with cryoglobulinemia extends the spectrum of
lymphoproliferative diseases associated with
HCV infection and adds further evidence to the
strengthening hypothesis of at least an indirect
influence of this viral infection on the neoplastic
transformation of some B lymphoid subsets. On
the other hand, further evidence for the ability
of HCV to directly infect and possibly deregu-
late specific populations of B lymphocytes is
provided by the recent demonstration of clonal
expansions of IgM-producing B cells, not only
in all patients with MC type II but also in about
one third of HCV-infected patients without
cryoglobulinemia.141 The increased serum levels
of rheumatoid factor in all patients with a clonal
expansion suggest that the expanded B cell
clones belong to the rheumatoid factor-produc-
ing B cell subset. It is widely accepted that HCV
RNA sequences cannot be integrated in the host
genome, so that a direct transforming role for
the virus in the lymphoproliferative process is
unlikely,109 although at least one nonstructural
protein, NS3, has been shown to have oncogenic
activity in vitro.142 Thus, the pathogenetic role of
HCV might be represented by the indirect
effects of chronic infection of lymphocytes, pos-
sibly representing the viral reservoir. One may
hypothesize that the virus, alone or in combina-
tion with other factors, i.e. genetic, infectious
and/or environmental, may produce (among
variable host responses) a proliferative response
of lymphoid elements to HCV antigens. On the
other hand, HCV may contribute to lymphoma-
genesis through alternative mechanisms by tak-
ing advantage of its tropism for salivary epithe-
lial cells in vivo. In fact, the localization of HCV
within a parotid NHL lesion in the course of
MC was recently described, and the residual
parotid epithelial cells were identified as the site
of viral infection and replication in the NHL
lesion.143 Furthermore, these cells may abnor-
mally express HLA class II antigens under
inflammatory conditions, and then act as true
antigen-presenting cells.143,144 In this lymphoma
case, HCV may have exerted its effect as an
exogenous stimulus able to sustain B cell lym-
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phoproliferation in either a T cell-independent
or -dependent process.143 Functional studies are
needed to gain insights into the possible patho-
genetic role of HCV in specific lymphoid neo-
plasias that is now suggested prevalently on the
basis of epidemiologic studies. 
Conclusions
The recent increase in knowledge about viral-
ly-associated lymphoproliferative diseases will
offer many advantages both for the use of molec-
ular techniques in diagnostics and for the devel-
opment of therapeutic strategies. For example,
PCR for EBV DNA in cerebrospinal fluid from
patients with AIDS is proposed to be a sensitive
and specific diagnostic tumor marker for the
presence of an AIDS-related primary lymphoma
of the central nervous system.145 Viral oncopro-
teins able to associate with cell-encoded proteins
may be exploited as a target for synthetic mole-
cules which can inhibit these complexes, with
possible therapeutic potential.70,146 Similarly, the
specific expression of virally-encoded proteins in
tumors may be exploited for cancer cell-specific
gene therapy.70 Knowledge about the biology of
EBV-induced lymphomas has led to the cure of
devastating immunoblastic lymphomas occur-
ring in recipients of allogeneic T-cell depleted
bone marrow by the simple infusion of
mononuclear cells from the EBV-seropositive
marrow donor, which supply EBV-specific pre-
cursor cytotoxic T lymphocytes able to recognize
EBV-infected lymphoma cells.147-149 The ability of
HHV-6 to integrate into chromosomal DNA at a
targeted site in vivo41,42 might be exploited for the
development of new viral vectors for gene thera-
py, analogously to adeno-associated virus (AAV),
which is the only other known DNA virus with
the ability to integrate into a targeted site
(19q13)150,151 and to be used as a vector for deliv-
ering genes into human hemopoietic cells.152-154
The demonstration of an antagonistic effect
between HHV-7 and HIV could be exploited to
develop new effective therapeutic approaches to
AIDS.75 The association of particular subsets of
NHL with HCV infection is an important new
acquisition that should be carefully considered
in clinical follow-up because of the possible
effects of chemotherapy on the course of the
HCV infection, as was recently emphasized by
the occurrence of fuminant hepatitis upon with-
drawal of chemotherapy in two carriers of HCV
infection also affected with lymphoma.155
Furthermore, the use of IFN may also repre-
sent a promising therapeutic option in patients
with HCV-associated lymphomas without cryo-
globulinemia. Since it has been reported that the
presence of HHV-8 sequences in the circulating
PBMCs of HIV-infected individuals might
reflect a propensity for developing KS,156 it is
possible that the presence of circulating HHV-8
sequences might also predict the development
of B cell lymphomas,78 or at least represent a
new indicator of immune dysregulation and
propensity for developing proliferations. The
role that HIV plays in the pathogenesis of B-cell
lymphomas in HIV-infected individuals has
always been thought to be indirect, as a result of
the effect of HIV on immunoregulation.7 0
However, the recent identification of a common
clonal HIV integration site, upstream from the
c-fes/fps proto-oncogene, in a few AIDS-associ-
ated T cell and mixed immunophenotype lym-
phomas suggested that HIV may contribute
directly to lymphomagenesis.157 The possible
interaction between HHV-8 and HIV in the set-
ting of AIDS-related lymphomagenesis might be
an important field of interest.
The years ahead will tell us whether the vast
amount of basic research on the biology of these
new lymphotropic viruses, namely HHV-6,
HHV-7, HHV-8 and HCV, may have an impact
on the clinical management of their associated
diseases.
Note added in proof
During revision of the manuscipt, Renne and
colleagues reported the development of a system
for the lytic growth of a latently HHV-8 infected
B cell line and presented the first ultrastructural
visualization of the virus.158
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